zilovertamab,ibrutinib
oncternal therapeutics,janssen,abbvie,merck
['zilovertamab', 'ibru', 'oncternal']
oncternal therapeutics presents rationale and plans for its registrational phase 3 study evaluating zilovertamab in combination with ibrutinib at the eha 2022 congress - diego, june 10, 2022 (globe newswire) -- oncternal therapeutics, inc. (nasdaq: on... 
CEO Of Digital Media Online